Perrigo Company has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets.

Mucinex 600mg Extended-Release tablets (Guaifenesin 600mg Extended-Release Tablets), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $135 million through food, drug and mass merchandisers for the last 12 months.

Perrigo's chairman and chief executive officer, Joseph C. Papa stated, "This re-launch is representative of the Perrigo team's abilities to overcome challenging circumstances presented by this product's complex formulation. The team worked diligently to validate and achieve consistency in producing commercial production quantities required to bring this product back to market. This is another excellent example of Perrigo's investment and commitment to making quality healthcare more affordable for our customers."  

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America.